- Patent Title: Treatment of retinitis pigmentosa using engineered meganucleases
-
Application No.: US16791687Application Date: 2020-02-14
-
Publication No.: US10758595B2Publication Date: 2020-09-01
- Inventor: Victor Bartsevich , Derek Jantz , James Jefferson Smith , Michael G. Nicholson
- Applicant: Precision BioSciences, Inc.
- Applicant Address: US NC Durham
- Assignee: Precision BioSciences, Inc.
- Current Assignee: Precision BioSciences, Inc.
- Current Assignee Address: US NC Durham
- Agency: Wolf, Greenfield & Sacks, P.C.
- Main IPC: C12N9/22
- IPC: C12N9/22 ; C12N15/55 ; C12N15/861 ; A61K38/46 ; C12N15/52 ; C12N15/90 ; A61P27/00
Abstract:
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
Public/Granted literature
- US20200179495A1 TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES Public/Granted day:2020-06-11
Information query
